Shares of Natera Inc (NASDAQ:NTRA) reached a new 52-week high on Monday after Cowen raised their price target on the stock from $30.00 to $42.00. Cowen currently has an average rating on the stock. Natera traded as high as $40.92 and last traded at $40.05, with a volume of 35352 shares traded. The stock had previously closed at $38.51.
A number of other analysts have also weighed in on NTRA. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. ValuEngine lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Craig Hallum upped their target price on shares of Natera from $29.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Piper Jaffray Companies set a $45.00 target price on shares of Natera and gave the stock a “buy” rating in a research note on Friday, October 11th. Finally, BidaskClub upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Natera presently has a consensus rating of “Buy” and a consensus target price of $38.40.
In related news, CFO Michael Burkes Brophy sold 43,954 shares of Natera stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $29.00, for a total transaction of $1,274,666.00. Following the sale, the chief financial officer now directly owns 26,690 shares in the company, valued at approximately $774,010. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Robert Alan Schueren sold 12,545 shares of Natera stock in a transaction on Friday, September 20th. The stock was sold at an average price of $33.19, for a total transaction of $416,368.55. Following the sale, the chief operating officer now owns 25,000 shares in the company, valued at $829,750. The disclosure for this sale can be found here. Insiders sold 438,947 shares of company stock valued at $13,888,596 over the last ninety days. 9.29% of the stock is currently owned by corporate insiders.
The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54. The company has a market capitalization of $2.70 billion, a PE ratio of -17.47 and a beta of 1.42. The company’s 50-day simple moving average is $34.39 and its 200-day simple moving average is $27.13.
Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.09. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The company had revenue of $74.36 million for the quarter, compared to the consensus estimate of $66.77 million. During the same period last year, the firm posted ($0.62) EPS. Natera’s revenue for the quarter was up 17.9% on a year-over-year basis. Analysts expect that Natera Inc will post -2.1 EPS for the current year.
Natera Company Profile (NASDAQ:NTRA)
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: Different Options Trading Strategies
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.